I-Mab Biopharma
I-Mab Biopharma, a leading player in the pharmaceutical preparation manufacturing industry, is headquartered in China (CN) and operates extensively across major regions, including North America and Europe. Founded in 2016, I-Mab has rapidly established itself as a pioneer in the development of innovative biologics, focusing on immuno-oncology and autoimmune diseases.
The company’s core offerings include monoclonal antibodies and other biologic therapies, distinguished by their unique mechanisms of action and potential to address unmet medical needs. I-Mab's commitment to research and development has led to significant milestones, including strategic partnerships and advancements in clinical trials. With a strong market position, I-Mab continues to make notable strides in the biopharmaceutical landscape, aiming to improve patient outcomes globally.
-20 vs industry average
I-Mab Biopharma’s score of 18 is lower than 26% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at I-Mab Biopharma?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Reported emissions
No reported emissions data is available for I-Mab Biopharma yet.
I-Mab Biopharma's reported carbon emissions
I-Mab Biopharma, a pharmaceutical preparation manufacturing company based in China, has not publicly disclosed specific figures for its carbon emissions. Consequently, detailed information regarding its Scope 1, Scope 2, or Scope 3 emissions is unavailable at this time.
While precise emissions data is not yet published, I-Mab Biopharma is expected to align with broader industry trends and regulatory expectations regarding climate action. Pharmaceutical companies globally are increasingly focusing on developing strategies to reduce their environmental footprint. This often involves setting greenhouse gas (GHG) reduction targets, improving energy efficiency in manufacturing processes, and exploring renewable energy sources. Future disclosures may provide insights into the company's progress in these areas and its commitment to mitigating climate change impacts.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
I-Mab Biopharma’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for I-Mab Biopharma yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
I-Mab Biopharma
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project